levetiracetam and Prostatic-Neoplasms

Brain metastases originate from other primary cancers within the body, most commonly lung, breast, and melanoma. Because patients with brain metastasis, stroke, or intracranial hemorrhage may present with similar acute neurologic symptoms, clinicians must have a high suspicion for brain metastasis and perform an immediate workup to rule out life-threatening conditions. This case report focuses on the clinical symptoms, diagnostics, and treatment options for brain metastasis in a patient with multiple malignancies.

Topics: Brain Neoplasms; Cranial Irradiation; Dexamethasone; Esophageal Neoplasms; Humans; Levetiracetam; Magnetic Resonance Imaging; Male; Melanoma; Neoplasms, Multiple Primary; Nervous System Diseases; Prostatic Neoplasms; Radiosurgery; Scalp; Seizures; Skin Neoplasms; Tomography, X-Ray Computed

A relevant fraction of castration-resistant prostate cancers (CRPC) evolve into fatal neuroendocrine (NEPC) tumors in resistance to androgen deprivation and/or inhibitors of androgen receptor pathway. Therefore, effective drugs against both CRPC and NEPC are needed. We have previously described a dual role of mast cells (MCs) in prostate cancer, being capable to promote adenocarcinoma but also to restrain NEPC. This finding suggests that a molecule targeting both MCs and NEPC cells could be effective against prostate cancer. Using an

Topics: Animals; Anticonvulsants; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Degranulation; Cell Differentiation; Cell Proliferation; Drug Repositioning; Gene Expression Regulation, Neoplastic; Humans; Levetiracetam; Male; Mast Cells; Matrix Metalloproteinase 9; Membrane Glycoproteins; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms, Experimental; Nerve Tissue Proteins; Prostatic Neoplasms; Tumor Cells, Cultured